Citius Oncology Net Income Over Time
| CTOR Stock | 1.13 0.02 1.80% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Citius Oncology Performance and Citius Oncology Correlation. Can Life Sciences Tools & Services industry sustain growth momentum? Does Citius have expansion opportunities? Factors like these will boost the valuation of Citius Oncology. Projected growth potential of Citius fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Citius Oncology demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Investors evaluate Citius Oncology using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Citius Oncology's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. External factors like market trends, sector rotation, and investor psychology can cause Citius Oncology's market price to deviate significantly from intrinsic value.
It's important to distinguish between Citius Oncology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Citius Oncology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Citius Oncology's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare Citius Oncology and related stocks such as Scilex Holding, Actuate Therapeutics, and Forte Biosciences Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SCLX | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (178.6 M) | (47.5 M) | (88.4 M) | (23.4 M) | (114.3 M) | (72.8 M) | (83.7 M) | (87.9 M) |
| ACTU | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (24.7 M) | (27.3 M) | (24.6 M) | (25.8 M) |
| FBRX | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (33.5 M) | (38.9 M) | (49 M) | (4.1 M) | (46.5 M) | (21.7 M) | (13.9 M) | (31.5 M) | (35.5 M) | (40.8 M) | (42.8 M) |
| SPRO | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (25.5 M) | (46.1 M) | (41.7 M) | (60.2 M) | (77.5 M) | (89.8 M) | (46.4 M) | 22.8 M | (68.6 M) | (61.7 M) | (64.8 M) |
| APLT | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (16.5 M) | (45.4 M) | (93 M) | (104.6 M) | (82.5 M) | (119.8 M) | (105.6 M) | (95.1 M) | (99.8 M) |
| VOR | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (10.8 M) | (43.3 M) | (68.9 M) | (92.1 M) | (117.9 M) | (116.9 M) | (105.2 M) | (100 M) |
| MCRB | (3.1 M) | (3.1 M) | (3.1 M) | (6.1 M) | (16.7 M) | (54.8 M) | (91.6 M) | (89.4 M) | (98.9 M) | (70.3 M) | (89.1 M) | (65.6 M) | (250.2 M) | (113.7 M) | 136 K | 122.4 K | 128.5 K |
| FATE | (13.4 M) | (13.4 M) | (14.2 M) | (20.9 M) | (25.9 M) | (30 M) | (33.5 M) | (43 M) | (66.6 M) | (98.1 M) | (173.4 M) | (212.2 M) | (255.1 M) | (160.9 M) | (186.3 M) | (167.6 M) | (159.3 M) |
| LNSR | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (14.7 M) | (19.8 M) | (19.6 M) | (19.9 M) | (14.4 M) | (31.4 M) | (28.3 M) | (29.7 M) |
| OWLT | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (17.9 M) | (10.5 M) | (71.7 M) | (79.3 M) | (32.9 M) | (12.5 M) | (11.3 M) | (11.8 M) |
Citius Oncology and related stocks such as Scilex Holding, Actuate Therapeutics, and Forte Biosciences Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Citius Oncology financial statement analysis. It represents the amount of money remaining after all of Citius Oncology operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Citius Oncology | CTOR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 11 Commerce Drive, |
| Exchange | NASDAQ Exchange |
null 1.13
Additional Tools for Citius Stock Analysis
When running Citius Oncology's price analysis, check to measure Citius Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology is operating at the current time. Most of Citius Oncology's value examination focuses on studying past and present price action to predict the probability of Citius Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology's price. Additionally, you may evaluate how the addition of Citius Oncology to your portfolios can decrease your overall portfolio volatility.